{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T12:28:21Z","timestamp":1750249701717,"version":"3.30.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clinthera.2024.09.011","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T17:04:24Z","timestamp":1728407064000},"page":"1024-1033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world Use of Mogamulizumab Among Patients With Mycosis Fungoides and S\u00e9zary Syndrome Before and During COVID-19 in the United States"],"prefix":"10.1016","volume":"46","author":[{"given":"Chunlan","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Ristuccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhishui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanobu","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eslie","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.09.011_bib0001","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2017.10.007","article-title":"Cutaneous T-cell lymphomas: focusing on novel agents in relapsed and refractory disease","volume":"61","author":"Argnani","year":"2017","journal-title":"Cancer Treatment Rev"},{"issue":"16","key":"10.1016\/j.clinthera.2024.09.011_bib0002","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 Update of the WHO-EORTC Classification for Primary Cutaneous Lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"year":"2023","series-title":"PDQ Mycosis Fungoides (Including S\u00e9zary Syndrome) Treatment","key":"10.1016\/j.clinthera.2024.09.011_sbref0003"},{"key":"10.1016\/j.clinthera.2024.09.011_bib0004","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Primary Cutaneous Lymphoma Version 1.2023. Available at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/primary_cutaneous.pdf. Accessed 2 February 2024."},{"key":"10.1016\/j.clinthera.2024.09.011_bib0005","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3390\/cancers13081931","article-title":"Mycosis Fungoides and S\u00e9zary Syndrome: an integrative review of the pathophysiology, molecular drivers, and targeted therapy","volume":"13","author":"Garc\u00eda-D\u00edaz","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.clinthera.2024.09.011_bib0006","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.3390\/cancers12102921","article-title":"Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients","volume":"12","author":"Dobos","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.clinthera.2024.09.011_bib0007","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jamaoncol.2022.3236","article-title":"Incidence trends of primary cutaneous T-cell lymphoma in the US from 2000 to 2018: a SEER population data analysis","volume":"8","author":"Cai","year":"2022","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.clinthera.2024.09.011_bib0008","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3109\/10428194.2012.729831","article-title":"Incidence and survival patters of cutaneous T-cell lymphomas in the United States","volume":"54","author":"Imam","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clinthera.2024.09.011_bib0009","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/hematology.2021000263","article-title":"What Factors Guide Treatment Selection in Mycosis Fungoides and Sezary Syndrome?","volume":"2021","author":"Kim","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1016\/j.clinthera.2024.09.011_bib0010","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.17258","article-title":"The PROCLIPI International Registry of Early-stage Mycosis Fungoides identifies substantial diagnostic delay in most patients","volume":"181","author":"Scarisbrick","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinthera.2024.09.011_bib0011","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis Fungoides\/S\u00e9zary Syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for research and treatment of cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clinthera.2024.09.011_bib0012","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1002\/cncr.27627","article-title":"Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas","volume":"118","author":"Quaglino","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2024.09.011_bib0013","unstructured":"American Society of Clinical Oncology. ASCO Special Report: A Guide to Cancer Care Delivery During the COVID-19 Pandemic. 2021. Available at https:\/\/old-prod.asco.org\/sites\/new-www.asco.org\/files\/content-files\/2020-ASCO-Guide-Cancer-COVID19.pdf. Accessed February 2, 2024."},{"key":"10.1016\/j.clinthera.2024.09.011_bib0014","unstructured":"POTELIGEO\u00ae Prescribing Information. 2023. Available at https:\/\/www.poteligeohcp.com\/assets\/files\/full-prescribing-information.pdf. Accessed February 2, 2024."},{"issue":"4","key":"10.1016\/j.clinthera.2024.09.011_bib0015","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/1060028019884863","article-title":"Mogamulizumab: an Anti-CC chemokine receptor 4 antibody for T-cell lymphomas","volume":"54","author":"Moore","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2024.09.011_bib0016","unstructured":"American Association for Cancer Research. AACR report on the impact of COVID-19 on cancer research and patient care. 2022. Available at https:\/\/www.aacr.org\/wp-content\/uploads\/2022\/02\/AACR_C19CR_2022.pdf. Accessed February 2, 2024."},{"issue":"35","key":"10.1016\/j.clinthera.2024.09.011_bib0017","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.15585\/mmwr.mm6935a2","article-title":"CDC Public Health Law Program; CDC COVID-19 Response Team, Mitigation Policy Analysis Unit. Timing of State and Territorial COVID-19 Stay-at-Home Orders and Changes in Population Movement \u2013 United States, March 1\u2013May 31, 2020","volume":"69","author":"Moreland","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"10.1016\/j.clinthera.2024.09.011_bib0018","doi-asserted-by":"crossref","first-page":"e936","DOI":"10.1634\/theoncologist.2020-0213","article-title":"A practical approach to the management of cancer patients during the Novel Coronavirus Disease 2019 (COVID-19) pandemic: an International Collaborative Group","volume":"25","author":"Al-Shamsi","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2024.09.011_bib0019","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1200\/GO.20.00423","article-title":"Delivering cancer care during the COVID-19 pandemic: recommendations and lessons learned from ASCO global webinars","volume":"6","author":"Jazieh","year":"2020","journal-title":"JCO Glob Oncol"},{"issue":"5","key":"10.1016\/j.clinthera.2024.09.011_bib0020","first-page":"504","article-title":"Safety at the time of the COVID-19 pandemic: how to keep our oncology patients and healthcare workers safe","volume":"18","author":"Cinar","year":"2020","journal-title":"JNCCN"},{"issue":"1","key":"10.1016\/j.clinthera.2024.09.011_bib0021","doi-asserted-by":"crossref","first-page":"e14463","DOI":"10.1111\/dth.14463","article-title":"Cutaneous lymphomas and COVID-19: what is known so far?","volume":"34","author":"Elmasry","year":"2021","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.clinthera.2024.09.011_bib0022","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaad.2020.04.049","article-title":"United States cutaneous lymphoma consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic","volume":"83","author":"Zic","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2024.09.011_bib0023","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/jdv.16593","article-title":"Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF Guidelines","volume":"34","author":"Papadavid","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.clinthera.2024.09.011_bib0024","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jaad.2022.11.016","article-title":"International Society for Cutaneous Lymphomas Pandemic Section (ICLYPS) analysis of cutaneous t-cell lymphoma outcomes during the COVID-19 pandemic: a retrospective cohort study","volume":"88","author":"Geskin","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2024.09.011_bib0025","unstructured":"Han A, Singh V, Rosenthal R, Kleczyk EW. Empowering clinical decisions using machine learning prediction of prognostic biomarkers for patient disease progression. 2022. Available at https:\/\/www.pmsa.org\/jpmsa-vol08-article04. Accessed February 2, 2024."},{"key":"10.1016\/j.clinthera.2024.09.011_bib0026","unstructured":"US Centers for Disease Control and Prevention. COVID Data Tracker Weekly Review. Don't run down the shot clock. 2021. Available at https:\/\/stacks.cdc.gov\/view\/cdc\/108434. Accessed February 2, 2024."},{"key":"10.1016\/j.clinthera.2024.09.011_bib0027","unstructured":"American Society of Clinical Oncology. ASCO cancer treatment & supportive care. 2022. Available at https:\/\/www.asco.org\/covid-resources\/patient-care-info\/cancer-treatment-supportive-care. Accessed 2 February 2024."},{"issue":"8","key":"10.1016\/j.clinthera.2024.09.011_bib0028","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.jgo.2020.07.008","article-title":"Adapting care for older cancer patients during the COVID-19 pandemic: recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group","volume":"11","author":"Battisti","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.clinthera.2024.09.011_bib0029","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.20.02953","article-title":"American Society of Clinical Oncology Road to Recovery Report: learning from the COVID-19 experience to improve clinical research and cancer care","volume":"39","author":"Pennell","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clinthera.2024.09.011_bib0030","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1097\/HS9.0000000000000529","article-title":"EHA\/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma: recommendations for the second phase of the COVID-19 pandemic","volume":"5","author":"Dreyling","year":"2021","journal-title":"Hemasphere"},{"issue":"5","key":"10.1016\/j.clinthera.2024.09.011_bib0031","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41571-020-0362-6","article-title":"Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic","volume":"17","author":"Hanna","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clinthera.2024.09.011_bib0032","doi-asserted-by":"crossref","first-page":"7591","DOI":"10.2147\/IJGM.S333501","article-title":"Barriers to Clinical Practice Guideline implementation among physicians: a physician survey","volume":"14","author":"Qumseya","year":"2021","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.clinthera.2024.09.011_bib0033","unstructured":"American Cancer Society. COVID-19 pandemic impact on cancer patients and survivors: survey findings summary. 2020. Available at https:\/\/www.fightcancer.org\/sites\/default\/files\/National%20Documents\/Survivor%20Views.COVID19%20Polling%20Memo.Final_.pdf. Accessed February 2, 2024."},{"key":"10.1016\/j.clinthera.2024.09.011_bib0034","unstructured":"American Cancer Society. COVID-19 Pandemic Ongoing Impact on Cancer Patients and Survivors: Survey Findings Summary. 2020. Available at https:\/\/www.fightcancer.org\/sites\/default\/files\/National%20Documents\/COVID19-Ongoing-Impact-Polling-Memo.pdf. Accessed February 2, 2024."},{"key":"10.1016\/j.clinthera.2024.09.011_bib0035","unstructured":"US Food & Drug Administration. FDA approves new dosing regimen for pembrolizumab. 2020. Available at https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-new-dosing-regimen-pembrolizumab. Accessed 2 February 2024."},{"issue":"11","key":"10.1016\/j.clinthera.2024.09.011_bib0036","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2022.4109","article-title":"Adoption of extended-interval dosing of single-agent pembrolizumab and comparative effectiveness vs standard dosing in time-to-treatment discontinuation","volume":"8","author":"Strohbehn","year":"2022","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.clinthera.2024.09.011_bib0037","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/cpt.1853","article-title":"Interventional pharmacoeconomics: a novel mechanism for unlocking value","volume":"108","author":"Serritella","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.clinthera.2024.09.011_bib0038","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41523-022-00393-2","article-title":"Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings","volume":"8","author":"Hsieh","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clinthera.2024.09.011_bib0039","unstructured":"US Centers for Disease Control and Prevention. Trends in Number of COVID-19 Cases and Deaths in the US Reported to CDC, by State\/Territory. Available at https:\/\/covid.cdc.gov\/covid-data-tracker\/#trends_weeklycases_select_00. Accessed 2 February 2024."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T20:00:41Z","timestamp":1733860841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824002753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0149291824002753"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Use of Mogamulizumab Among Patients With Mycosis Fungoides and S\u00e9zary Syndrome Before and During COVID-19 in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}